| Dominic Joseph Cottrell, MD | |
|
1824 Murdoch Ave, Parkersburg, WV 26101-3230 | |
| (304) 424-4695 | |
| (304) 422-3924 |
| Full Name | Dominic Joseph Cottrell |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 28 Years |
| Location | 1824 Murdoch Ave, Parkersburg, West Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558340174 | NPI | - | NPPES |
| 1841933000 | Medicaid | WV | |
| 2411223 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 19769 (West Virginia) | Primary |
| 207L00000X | Anesthesiology | 35087051 (Ohio) | Secondary |
| 207L00000X | Anesthesiology | 200101192 (North Carolina) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wheeling Hospital | Wheeling, WV | Hospital |
| Reynolds Memorial Hospital | Glen dale, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wheeling Hospital Inc | 5799689493 | 319 |
| United Hospital Center Inc | 8123936010 | 209 |
| Reynolds Memorial Hospital, Inc | 9830184530 | 122 |
News Archive
Quick-Med Technologies, Inc. announced today that it has successfully completed its joint development program with Foster Corporation, a member of PolyMedex Discovery Group, to collaborate in applying Quick-Med's proprietary NIMBUS® technology to thermoplastics for catheters and other medical product applications.
International Stem Cell Corporation, announced today that it had entered into a Memorandum of Understanding with ARG Vermogensverwaltung AG, a German Investment Fund, to create a new European subsidiary ("ISCO Europe") to be funded with up to $10 million of capital derived from ARG and other independent sources in Europe. Shares of ISCO Europe are expected to trade on the Deutsche Bourse independently of the company's shares in the US. ISCO Europe's shares will not be convertible into ISCO shares on any US exchange.
Johns Hopkins researchers report success with a smart phone video-based app that substitutes for a daily in-person visit by a health care worker required for tuberculosis treatment known as directly observed therapy, or DOT.
Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc. U.S., submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone for the treatment of hypertension, or high blood pressure.
› Verified 4 days ago
| Entity Name | West Virginia University Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275504508 PECOS PAC ID: 1052224565 Enrollment ID: O20031111000207 |
News Archive
Quick-Med Technologies, Inc. announced today that it has successfully completed its joint development program with Foster Corporation, a member of PolyMedex Discovery Group, to collaborate in applying Quick-Med's proprietary NIMBUS® technology to thermoplastics for catheters and other medical product applications.
International Stem Cell Corporation, announced today that it had entered into a Memorandum of Understanding with ARG Vermogensverwaltung AG, a German Investment Fund, to create a new European subsidiary ("ISCO Europe") to be funded with up to $10 million of capital derived from ARG and other independent sources in Europe. Shares of ISCO Europe are expected to trade on the Deutsche Bourse independently of the company's shares in the US. ISCO Europe's shares will not be convertible into ISCO shares on any US exchange.
Johns Hopkins researchers report success with a smart phone video-based app that substitutes for a daily in-person visit by a health care worker required for tuberculosis treatment known as directly observed therapy, or DOT.
Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc. U.S., submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone for the treatment of hypertension, or high blood pressure.
› Verified 4 days ago
| Entity Name | Wheeling Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104821305 PECOS PAC ID: 5799689493 Enrollment ID: O20031124000706 |
News Archive
Quick-Med Technologies, Inc. announced today that it has successfully completed its joint development program with Foster Corporation, a member of PolyMedex Discovery Group, to collaborate in applying Quick-Med's proprietary NIMBUS® technology to thermoplastics for catheters and other medical product applications.
International Stem Cell Corporation, announced today that it had entered into a Memorandum of Understanding with ARG Vermogensverwaltung AG, a German Investment Fund, to create a new European subsidiary ("ISCO Europe") to be funded with up to $10 million of capital derived from ARG and other independent sources in Europe. Shares of ISCO Europe are expected to trade on the Deutsche Bourse independently of the company's shares in the US. ISCO Europe's shares will not be convertible into ISCO shares on any US exchange.
Johns Hopkins researchers report success with a smart phone video-based app that substitutes for a daily in-person visit by a health care worker required for tuberculosis treatment known as directly observed therapy, or DOT.
Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc. U.S., submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone for the treatment of hypertension, or high blood pressure.
› Verified 4 days ago
| Entity Name | United Hospital Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760965586 PECOS PAC ID: 8123936010 Enrollment ID: O20031212000802 |
News Archive
Quick-Med Technologies, Inc. announced today that it has successfully completed its joint development program with Foster Corporation, a member of PolyMedex Discovery Group, to collaborate in applying Quick-Med's proprietary NIMBUS® technology to thermoplastics for catheters and other medical product applications.
International Stem Cell Corporation, announced today that it had entered into a Memorandum of Understanding with ARG Vermogensverwaltung AG, a German Investment Fund, to create a new European subsidiary ("ISCO Europe") to be funded with up to $10 million of capital derived from ARG and other independent sources in Europe. Shares of ISCO Europe are expected to trade on the Deutsche Bourse independently of the company's shares in the US. ISCO Europe's shares will not be convertible into ISCO shares on any US exchange.
Johns Hopkins researchers report success with a smart phone video-based app that substitutes for a daily in-person visit by a health care worker required for tuberculosis treatment known as directly observed therapy, or DOT.
Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc. U.S., submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone for the treatment of hypertension, or high blood pressure.
› Verified 4 days ago
| Entity Name | Reynolds Memorial Hospital, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518068014 PECOS PAC ID: 9830184530 Enrollment ID: O20040420000896 |
News Archive
Quick-Med Technologies, Inc. announced today that it has successfully completed its joint development program with Foster Corporation, a member of PolyMedex Discovery Group, to collaborate in applying Quick-Med's proprietary NIMBUS® technology to thermoplastics for catheters and other medical product applications.
International Stem Cell Corporation, announced today that it had entered into a Memorandum of Understanding with ARG Vermogensverwaltung AG, a German Investment Fund, to create a new European subsidiary ("ISCO Europe") to be funded with up to $10 million of capital derived from ARG and other independent sources in Europe. Shares of ISCO Europe are expected to trade on the Deutsche Bourse independently of the company's shares in the US. ISCO Europe's shares will not be convertible into ISCO shares on any US exchange.
Johns Hopkins researchers report success with a smart phone video-based app that substitutes for a daily in-person visit by a health care worker required for tuberculosis treatment known as directly observed therapy, or DOT.
Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc. U.S., submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone for the treatment of hypertension, or high blood pressure.
› Verified 4 days ago
| Entity Name | Medical Park Anesthesiologists Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376764985 PECOS PAC ID: 9436191046 Enrollment ID: O20050524001000 |
News Archive
Quick-Med Technologies, Inc. announced today that it has successfully completed its joint development program with Foster Corporation, a member of PolyMedex Discovery Group, to collaborate in applying Quick-Med's proprietary NIMBUS® technology to thermoplastics for catheters and other medical product applications.
International Stem Cell Corporation, announced today that it had entered into a Memorandum of Understanding with ARG Vermogensverwaltung AG, a German Investment Fund, to create a new European subsidiary ("ISCO Europe") to be funded with up to $10 million of capital derived from ARG and other independent sources in Europe. Shares of ISCO Europe are expected to trade on the Deutsche Bourse independently of the company's shares in the US. ISCO Europe's shares will not be convertible into ISCO shares on any US exchange.
Johns Hopkins researchers report success with a smart phone video-based app that substitutes for a daily in-person visit by a health care worker required for tuberculosis treatment known as directly observed therapy, or DOT.
Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc. U.S., submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone for the treatment of hypertension, or high blood pressure.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dominic Joseph Cottrell, MD 3211 Dudley Ave, Parkersburg, WV 26104-1813 Ph: (304) 422-3904 | Dominic Joseph Cottrell, MD 1824 Murdoch Ave, Parkersburg, WV 26101-3230 Ph: (304) 424-4695 |
News Archive
Quick-Med Technologies, Inc. announced today that it has successfully completed its joint development program with Foster Corporation, a member of PolyMedex Discovery Group, to collaborate in applying Quick-Med's proprietary NIMBUS® technology to thermoplastics for catheters and other medical product applications.
International Stem Cell Corporation, announced today that it had entered into a Memorandum of Understanding with ARG Vermogensverwaltung AG, a German Investment Fund, to create a new European subsidiary ("ISCO Europe") to be funded with up to $10 million of capital derived from ARG and other independent sources in Europe. Shares of ISCO Europe are expected to trade on the Deutsche Bourse independently of the company's shares in the US. ISCO Europe's shares will not be convertible into ISCO shares on any US exchange.
Johns Hopkins researchers report success with a smart phone video-based app that substitutes for a daily in-person visit by a health care worker required for tuberculosis treatment known as directly observed therapy, or DOT.
Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc. U.S., submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone for the treatment of hypertension, or high blood pressure.
› Verified 4 days ago
Dr. John Stewart Haid, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 800 Garfield Ave, Parkersburg, WV 26101 Phone: 304-424-2590 | |
Dr. Ophelia Diaz Cansino, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 800 Garfield Ave, Parkersburg, WV 26101 Phone: 304-424-2590 Fax: 304-422-3924 | |
Dr. Ignacio Cardenas, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 800 Garfield Ave, Parkersburg, WV 26101 Phone: 304-424-2590 Fax: 304-422-3924 | |
Dr. Ruben Castro Estrada, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 800 Garfield Ave, Parkersburg, WV 26101 Phone: 304-424-2590 Fax: 304-422-3924 | |
D'ann Elizabeth Duesterhoeft, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 800 Garfield Ave, Parkersburg, WV 26101 Phone: 304-424-2590 Fax: 304-422-3924 | |
Robert D Bailiff, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3211 Dudley Ave, Parkersburg, WV 26104 Phone: 304-422-3904 Fax: 304-422-3924 |